Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.

Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.

Diabetes Obes Metab. 2013 Mar;15(3):264-71. doi: 10.1111/dom.12026. Epub 2012 Nov 12.

2.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

3.
4.

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.

Aroda VR, DeYoung MB.

Postgrad Med. 2011 Sep;123(5):228-38. doi: 10.3810/pgm.2011.09.2479. Review.

PMID:
21904106
5.

Once weekly exenatide: efficacy, tolerability and place in therapy.

Wysham C, Grimm M, Chen S.

Diabetes Obes Metab. 2013 Oct;15(10):871-81. doi: 10.1111/dom.12084. Epub 2013 Mar 24. Review.

PMID:
23425609
6.

Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.

Stonehouse A, Walsh B, Cuddihy R.

Diabetes Technol Ther. 2011 Oct;13(10):1063-9. doi: 10.1089/dia.2011.0076. Epub 2011 Jul 6. Review.

7.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
8.

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

Ryan GJ, Moniri NH, Smiley DD.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Review.

PMID:
23784159
9.

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.

Holst JJ, Vilsbøll T.

Diabetes Obes Metab. 2013 Jan;15(1):3-14. doi: 10.1111/j.1463-1326.2012.01628.x. Epub 2012 Jun 29. Review.

PMID:
22646532
10.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

11.

Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Rosenstock J, Fitchet M.

Int J Clin Pract Suppl. 2008 Mar;(159):15-23. doi: 10.1111/j.1742-1241.2007.01692.x. Review.

PMID:
18269437
12.

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.

Best JH, Lavillotti K, DeYoung MB, Garrison LP.

Diabetes Obes Metab. 2012 May;14(5):387-98. doi: 10.1111/j.1463-1326.2011.01533.x. Epub 2011 Dec 27. Review.

PMID:
22074017
13.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

14.

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

Davies M, Speight J.

Diabetes Obes Metab. 2012 Oct;14(10):882-92. doi: 10.1111/j.1463-1326.2012.01595.x. Epub 2012 Apr 17. Review.

PMID:
22420869
15.

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Balena R, Hensley IE, Miller S, Barnett AH.

Diabetes Obes Metab. 2013 Jun;15(6):485-502. doi: 10.1111/dom.12025. Epub 2012 Nov 12. Review.

16.

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.

Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.

Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Review.

PMID:
22985213
17.

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH.

Diabetes Obes Metab. 2014 May;16(5):433-42. doi: 10.1111/dom.12239. Epub 2013 Dec 16. Review.

PMID:
24237939
18.

Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, Rajagopalan S.

Am J Hypertens. 2014 Jan;27(1):130-9. doi: 10.1093/ajh/hpt196. Epub 2013 Nov 21. Review.

PMID:
24263424
19.

Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.

Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ.

Ann Intern Med. 2016 Jan 19;164(2):102-13. doi: 10.7326/M15-1432. Epub 2015 Dec 8. Review.

PMID:
26642233
20.

Once-weekly exenatide as a treatment for Type 2 diabetes.

Schauerhamer MB, Gurgle H, McAdam-Marx C.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):611-26. doi: 10.1586/14779072.2015.1038242. Review.

PMID:
26000560
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk